Ownership and insider activity for COMPASS Pathways plc (CMPS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder.
Price
| Price | $13.80 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | GB |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-03 | Nath Kabir | F-InKind | 5,962 | $67K |
| 2026-05-27 | Karydas Daphne | A-Award | 21,110 | $250K |
| 2026-05-27 | SANTINI GINO | A-Award | 30,158 | $357K |
| 2026-05-27 | Gover Justin D. | A-Award | 21,110 | $250K |
| 2026-05-27 | JONAS JEFFREY M | A-Award | 21,110 | $250K |
| 2026-05-27 | Riley Wayne Joseph | A-Award | 21,110 | $250K |
| 2026-05-27 | McQuade Robert | A-Award | 21,110 | $250K |
| 2026-05-27 | Norton David Y | A-Award | 21,110 | $250K |
| 2026-05-27 | Tregoning Kathleen | A-Award | 41,119 | $487K |
| 2026-05-27 | Tregoning Kathleen |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.9M | $25.0M | $190.3M | $273.2M | $143.2M | $220.2M | $165.1M | $149.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $2.1M | 0 | 0 | $11.2M | $15.6M | $28.9M | $21.8M | $15.4M |
| Inventory | $943000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $26.3M | $32.2M | $202.4M | $295.3M | $191.7M | $261.3M | $201.3M | $191.5M |
| Property, Plant & Equipment | $108000 | $218000 | $245000 | $4.1M | $2.6M | $4.7M | $2.2M | $3.4M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $26.4M | $32.4M | $203.5M | $300.9M | $197.3M | $276.0M | $213.7M | $210.3M |
| Accounts Payable | $694000 | $1.3M | $2.7M | $2.6M | $4.8M | $5.9M | $12.3M | $15.2M |
| Short-term Debt | 0 | $21.1M | 0 | 0 | 0 | 0 | $5.5M | $19.6M |
| Total Current Liabilities | $1.8M | $23.9M | $6.9M | $15.1M | $15.6M | $19.6M | $34.0M | $247.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $28.8M | $24.7M | $1.3M |
| Total Liabilities | $40.8M | $23.9M | $6.9M | $16.5M | $16.0M | $50.2M | $59.0M | $263.2M |
| Retained Earnings | -$18.0M | -$37.6M | -$97.9M | -$169.6M | -$261.1M | -$379.6M | -$534.7M | -$822.6M |
| Total Equity | -$14.4M | $8.5M | $196.6M | $284.4M | $181.3M | $225.7M | $154.7M | -$52.8M |
| Total Debt | 0 | $21.1M | 0 | $3.6M | $1.9M | $33.0M | $32.2M | $20.9M |
| Net Debt | -$22.9M | -$3.9M | -$190.3M | -$269.6M | -$141.3M | -$187.1M | -$132.9M | -$128.7M |
| Working Capital | $24.4M | $8.3M | $195.5M | $280.2M | $176.1M | $241.7M | $167.3M | -$56.3M |
Financial Health
| Debt / Equity | 0.65 |
| Current Ratio | 1.30 |
Profitability
| Return on Equity | -398.21% |
| Return on Invested Capital | -129.74% |
| Return on Assets | -78.12% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AVNS · CYH · EHAB · FDMT · GOSS · KALV · PRTA
Explore sector: Healthcare · Biotechnology
More sections of CMPS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks